Nicolai Stransky
Overview
Explore the profile of Nicolai Stransky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
33
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ganser K, Stransky N, Abed T, Quintanilla-Martinez L, Gonzalez-Menendez I, Naumann U, et al.
Int J Cancer
. 2024 Jun;
155(10):1886-1901.
PMID: 38938062
Prognosis of glioblastoma patients is still poor despite multimodal therapy. The highly brain-infiltrating growth in concert with a pronounced therapy resistance particularly of mesenchymal glioblastoma stem-like cells (GSCs) has been...
2.
Stransky N, Ganser K, Quintanilla-Martinez L, Gonzalez-Menendez I, Naumann U, Eckert F, et al.
Sci Rep
. 2023 Nov;
13(1):20604.
PMID: 37996600
The intermediate-conductance calcium-activated potassium channel K3.1 has been proposed to be a new potential target for glioblastoma treatment. This study analyzed the effect of combined irradiation and K3.1-targeting with TRAM-34...
3.
Abed T, Ganser K, Eckert F, Stransky N, M Huber S
Front Cell Neurosci
. 2023 Apr;
17:1133984.
PMID: 37006466
Therapies with weak, non-ionizing electromagnetic fields comprise FDA-approved treatments such as Tumor Treating Fields (TTFields) that are used for adjuvant therapy of glioblastoma. data and animal models suggest a variety...
4.
Heise V, Holman C, Lo H, Lyras E, Adkins M, Aquino M, et al.
PLoS Comput Biol
. 2023 Jan;
19(1):e1010750.
PMID: 36602968
Open, reproducible, and replicable research practices are a fundamental part of science. Training is often organized on a grassroots level, offered by early career researchers, for early career researchers. Buffet...
5.
Stransky N, Ganser K, Naumann U, M Huber S, Ruth P
Cancers (Basel)
. 2022 Dec;
14(24).
PMID: 36551685
Reportedly, the intermediate-conductance Ca-activated potassium channel K3.1 contributes to the invasion of glioma cells into healthy brain tissue and resistance to temozolomide and ionizing radiation. Therefore, K3.1 has been proposed...
6.
Stransky N, M Huber S
Biomolecules
. 2022 Apr;
12(4).
PMID: 35454162
In the study of Chen et al. [...].
7.
Ganser K, Eckert F, Riedel A, Stransky N, Paulsen F, Noell S, et al.
Int J Cancer
. 2022 Jan;
150(10):1722-1733.
PMID: 35085407
Identification of prognostic or predictive molecular markers in glioblastoma resection specimens may lead to strategies for therapy stratification and personalized treatment planning. Here, we analyzed in primary glioblastoma stem cell...
8.
Stransky N, Ruth P, Schwab M, Loffler M
Cancers (Basel)
. 2021 Dec;
13(24).
PMID: 34944859
Drug repurposing is a complementary pathway for introducing new drugs against cancer. Broad systematic assessments of ongoing repurposing efforts in oncology are lacking, but may be helpful to critically appraise...
9.
Zirjacks L, Stransky N, Klumpp L, Prause L, Eckert F, Zips D, et al.
Biomolecules
. 2021 Nov;
11(11).
PMID: 34827559
Mesenchymal glioblastoma stem cells (GSCs), a subpopulation in glioblastoma that are responsible for therapy resistance and tumor spreading in the brain, reportedly upregulate aldehyde dehydrogenase isoform-1A3 (ALDH1A3) which can be...
10.
Vatter T, Klumpp L, Ganser K, Stransky N, Zips D, Eckert F, et al.
Biomolecules
. 2020 Jun;
10(6).
PMID: 32560384
Methadone, which is used as maintenance medication for outpatient treatment of opioid dependence or as an analgesic drug, has been suggested by preclinical in vitro and mouse studies to induce...